Kezar Life Sciences

Please note: The information displayed on this page might be outdated.
Kezar Life Sciences: Clinical stage biotechnology company pioneering first-in-class, small molecule therapies designed to inhibit multiple disease-driving cellular pathways by targeting key intracellular proteins. The Company is advancing two differentiated therapeutic approaches: Selective Immunoproteasome Inhibition, for the treatment of autoimmune diseases through immune modulation versus direct immunosuppression; and Protein Secretion Inhibition, halting the secretion of target proteins that contribute to a range of cancers and autoimmune diseases. Lead candidate, zetomipzomib (KZR-616), a selective immunoproteasome inhibitor, is being evaluated in Phase 2 clinical trials for lupus nephritis and autoimmune hepatitis, and KZR-261, a first-in-class inhibitor of the Sec61 translocon developed using the Company’s novel discovery Protein Secretion Inhibition Platform, is undergoing a Phase 1 clinical trial for the treatment of advanced/metastatic solid tumors.
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Oncology
Public, USA
Market Cap
Therapeutic Modalities
Small Molecule
4000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States

Company Participants at Solebury 1x1 Management Access Event 2023

  • John Fowler, CEO, Co-Founder
  • Marc L. Belsky, Chief Financial Officer
  • Nick Mordwinkin , PhD, Chief Business Officer
  • Noreen Henig, MD, CMO

Top 10 Holders of Kezar Life Sciences Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Suvretta Capital Management LLC 9.90 7,167,591 8.53 13F 6/30/23
Avidity Partners Management LP 8.40 6,080,000 7.24 13F 6/30/23
OrbiMed Advisors LLC 7.54 5,463,000 6.50 13F 6/30/23
Prosight Management LP 6.42 4,651,920 5.54 13F 6/30/23
Millennium Management LLC 5.17 3,741,109 4.45 13F 6/30/23
Vanguard Group, Inc. (Subfiler) 4.12 2,982,519 3.55 13F 6/30/23
BlackRock Fund Advisors 4.07 2,949,364 3.51 13F 6/30/23
Sphera Funds Management Ltd. 2.75 1,988,228 2.37 13F 6/30/23
OrbiMed Advisors Private Equity 2.65 1,927,000 2.29 Funds 8/31/23
Granahan Investment Management, LLC 2.62 1,899,019 2.26 13F 6/30/23
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.